Zanzalintinib (XL092)

Name: Zanzalintinib (XL092) in Metastatic colorectal cancer: Indication
Published: 2026-09-14T15:39:06-04:00

Metastatic colorectal cancer

Manufacturer: Exelixis
Regulatory submission: NDA submitted December 2025
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

Indication

1 evidence topic · 1 source

Proposed indication and prior treatment requirements

“adult patients with metastatic colorectal cancer” (opens the source at this quote in a new tab)
“previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, and, if RAS wild-type, an anti-epidermal growth factor receptor (EGFR) therapy.” (opens the source at this quote in a new tab)